EGFR and non-small cell lung carcinoma: In a phase 2b study, the CNS objective response rate (ORR) of furmonertinib 80 mg orally once daily in EGFR T790M mutated NSCLC patients was 66% and the median CNS-PFS was 11.6 months [17].